China is the world's largest market for regulated stem cell therapy — and the only place many programs are legally available to international patients. Here's what licensed hospitals actually offer for type 1 and type 2 diabetes, what it really costs, and how to avoid the hype.
Updated August 2026. Stem cell therapy is one of the most searched — and most abused — categories in medical tourism. The good news: China's regulatory framework (NMPA + the Hainan Boao Lecheng pilot zone) has created a legitimate, licensed pathway that treats international patients. The bad news: most English-language brokers don't use it. Here's the honest picture.
Licensed stem cell programs in China operate under two frameworks:
For diabetes specifically, the current evidence base centers on:
| Program | Typical all-in range | What's included |
|---|---|---|
| Type 1 diabetes stem cell program | $23,000–39,000 | Hospital, physician, cell product, nursing, room, translation, coordination |
| Type 2 diabetes program | $18,000–30,000 | Hospital, physician, cell product, nursing, room, translation, coordination |
| Eligibility workup (pre-travel) | $800–2,000 | Records review, remote physician consult, screening labs |
| Follow-up program (12 months) | $2,000–5,000 | Remote monitoring, telehealth consults, lab coordination |
Compare: US stem cell clinics routinely charge $50,000–150,000 for unproven, FDA-unsanctioned treatments with zero regulatory oversight. China's licensed Boao pathway is typically 30–60% less and operates under a real regulatory framework with a real hospital behind it.
China's Hainan Free Trade Port and the Boao Lecheng International Medical Tourism Pilot Zone are the government-designated venue for advanced licensed therapies. Key facts:
We only coordinate with zone-licensed hospitals with JCI or equivalent accreditation, English-speaking international departments, and documented experience with foreign patients. Every hospital is verified before it enters our network.
Stem cell tourism has a well-earned reputation problem — largely because patients wire six figures to unlicensed clinics that vanish. Our structure:
Because results are documented and reviews are tied to case files, our published patient ledger grows in credibility over time. That's the moat — and it's why we publish what programs can and cannot do.
Yes — in licensed facilities under the NMPA clinical-trial framework or the Boao Lecheng pilot zone's licensed-treatment framework. We do not coordinate with unlicensed clinics, and we will tell you if a program you found online is not licensed.
No licensed program requires you to stop insulin. Programs aim to reduce dependence over time under medical supervision. Anyone who tells you to stop insulin before or during treatment should be a red flag.
Typically 2–4 weeks for the initial program, depending on the protocol. Follow-up is remote for up to 12 months.
Every review links to a case file verified against the treatment contract and hospital records. We re-verify reviewers before publication — fabricated reviews would void our escrow terms.
Describe your case and current treatment. We'll respond within one business day.